University of Leicester
University of Cambridge
Andreas LoukasHead of Biologics AI · Isomorphic LabsResearcher↗
Researcher
Miles Congreve
Isomorphic LabsChief Scientific Officer
Congreve is a medicinal chemist who pioneered fragment-based drug discovery at Astex and structure-based design for GPCR targets at Sosei Heptares, and is co-inventor of the breast-cancer drug Kisqali (ribociclib).[1] He is Chief Scientific Officer at Isomorphic Labs and was named to the 2025 TIME 100 AI list.[2]
Career & education
Current roleIsomorphic Labs2022-presentChief Scientific Officer
Isomorphic Labs2022-presentPreviously
Sosei Heptares2008-2022
Chief Scientific OfficerWork and education history is primarily focused on AI-relevant roles and may not be comprehensive.
Citation Trend
Total citations to scholarly work, including research papers, technical reports, books and theses, as recorded by Google Scholar. Each point is a dated snapshot.
citations35,863As of Oct 28, '26
citations+5,331Since last snapshot, Jun 15, '26
Selected contributions
Accurate structure prediction of biomolecular interactions with AlphaFold 3
With Josh Abramson, Jonas Adler, Jack Dunger, Richard Evans, Tim Green, Alexander Pritzel, Olaf Ronneberger and others ·AlphaFold 3 predicts how proteins, DNA, RNA and other molecules fit together.
References
- Miles Congreve — Isomorphic Labsisomorphiclabs.com
His official biography documents the Astex and Sosei Heptares work, his co-invention of ribociclib, and his current chief scientific officer role.
- TIME100 AI 2025 — Miles Congrevetime.com
TIME’s own 2025 TIME100 AI collection profile confirms his inclusion.
Based on public sources. If accuracy is important, verify details using the links or references.
For corrections, updates, or requests to remove information, contact us.
Reviewed August 15, 2026 · Checked for accuracy and new information.
